Sanjay Goel

1 month ago | ajmc.com | Pearl Steinzor |Sanjay Goel

Ahead of the American Society of Clinical Oncology (ASCO) 2025 annual meeting, Sanjay Goel, MD, MS, professor of medicine at Robert Wood Johnson Medical School and medical oncologist at Rutgers Cancer Institute, shared his excitement for the many sessions that will be presented at this year's conference.

Nov 8, 2024 | tandfonline.com | Byoung Chul Cho |Lyudmila A Bazhenova |Dong-Wan Kim |Sanjay Goel

AbstractAim: We report clinical activity and safety of sitravatinib in patients with advanced cancer from basket cohorts with specific molecular alterations, in a Phase Ib study. Materials & methods: Patients with advanced solid tumors harboring amplification, mutation, or rearrangement of MET, AXL, RET, NTRK, DDR2, KDR, PDGFRA, KIT or CBL received sitravatinib once daily. Primary end point was confirmed objective response rate (ORR).

Aug 21, 2024 | nature.com | Midhun Malla |Timothy Samec |Heinz-Josef Lenz |Emil Lou |Sanjay Goel |Dane C. Olevian

AbstractThe expression of the protein Mesothelin (MSLN) is highly variable in several malignancies, including colorectal cancer (CRC), and high levels are associated with aggressive clinicopathological features and worse patient survival. Colorectal cancer is both a common and deadly cancer; being the third most common in incidence and second most common cause of cancer-related death.

Sep 1, 2023 | onclive.com | Sanjay Goel

Sanjay Goel, MD, MS, director, Phase I/Investigational Therapeutics, Rutgers Cancer Institute of New Jersey; professor, medicine, Division of Medical Oncology, Section of Solid Tumors, Rutgers Robert Wood Johnson Medical School, discusses the safety profile of the TKI tinengotinib (TT-00420) as a monotherapy and in combination with chemotherapy in patients with solid tumors.

Aug 30, 2023 | onclive.com | Sanjay Goel

Sanjay Goel, MD, MS, director, Phase I/Investigational Therapeutics, Rutgers Cancer Institute of New Jersey; professor, medicine, Division of Medical Oncology, Section of Solid Tumors, Rutgers Robert Wood Johnson Medical School, discusses the mechanism of action of tinengotinib (TT-00420) and the efficacy of this agent in patients with cholangiocarcinoma.